Magrolimab Shows Promise in MDS and AML - Targeted Oncology

Retrieved on: 2022-10-04 18:06:53

Tags for this article:

RTT

Cancer

Acute myeloid leukemia

Myelodysplastic syndrome

Drugs

Azacitidine

Vadastuximab talirine

the university of texas md anderson cancer center

Click the tags to see associated articles and topics

Magrolimab Shows Promise in MDS and AML - Targeted Oncology. View article details on HISWAI: https://www.targetedonc.com/view/magrolimab-shows-promise-in-mds-and-aml

Excerpt

Naval G. Daver, MD, discusses the latest research on magrolimab, a CD47 monoclonal antibody, for patients with acute myeloid leukemia and ...

Article found on: www.targetedonc.com

View Original Article